Results 261 to 270 of about 5,785,217 (307)
Some of the next articles are maybe not open access.
Tacrolimus in hematopoietic stem cell transplantation
Expert Opinion on Drug Metabolism & Toxicology, 2009Graft-versus-host disease (GVHD) associated with allogeneic peripheral blood or marrow transplantation is a serious life-threatening complication. Most of the available literature support the use of tacrolimus as a prophylactic agent for acute GVHD.To review the pharmacology, efficacy and safety of tacrolimus and recommend its place in therapy for the ...
Kara, Fortune, Daniel, Couriel
openaire +2 more sources
Hematopoietic stem cell transplantation in infants
Pediatric Blood & Cancer, 2014BackgroundIt is rare for infants, who are less than 365 days old, to receive hematopoietic stem cell transplantation (HSCT). Our objective was to review the indications, survival, and late effects of infants who received HSCT.ProcedureBetween April 1992 and March 2010, a total of 1,363 children underwent HSCT (775 allogeneic [allo]; 588 autologous ...
Adam, Gassas +7 more
openaire +2 more sources
Hematopoietic Stem Cell Transplantation for Thalassemia
Immunotherapy, 2012Thalassemia is an autosomal recessive disorder associated with defective synthesis of the α- or β-chain of hemoglobin. For β-thalassemia major patients, therapeutic options are either monthly red cell transfusions and chelation therapy or allogeneic stem cell transplant.
Yasser, Elborai +2 more
openaire +2 more sources
Hematopoietic Stem-Cell Transplantation
New England Journal of Medicine, 2006Hematopoietic stem-cell transplantation, which is used to treat both malignant and nonmalignant conditions, was first conceived more than 50 years ago, but problems associated with transplanting a nonsolid organ and modulating the immune response had to be solved before the procedure could be used clinically.
openaire +2 more sources
Hematopoietic Stem Cell Transplantation in Thalassemia
Hematology/Oncology Clinics of North America, 2018Although recent advances in gene therapy are expected to increase the chance of disease cure in thalassemia major, at present hematopoietic stem cell transplantation (HSCT) remains the only consolidated curative approach for this disorder. The widest experience has been obtained in the HLA-matched family donor (MFD) setting, with probabilities of ...
Strocchio L., Locatelli F.
openaire +4 more sources
Hematopoietic Stem Cell Transplantation in Children
Critical Care Nursing Clinics of North America, 2011Medical and nursing care of the hematopoietic stem cell transplantation (HSCT) recipient are complex because of the pathophysiology, HSCT process, pre-HSCT conditioning regimens, numerous medications and therapies, acute and chronic complications, adverse effects, resources involved, and environmental considerations.
Julie A, Kolins +3 more
openaire +2 more sources
Proteomics for hematopoietic stem cell transplantation
Expert Review of Proteomics, 2020Introduction: After the genomic era, the analysis of the proteome has gained increasing importance. Peptides and/or proteins present in tissue or body fluids can depict health and are prone to change during disease, not only in configuration but also in abundance.
Eva M, Weissinger +4 more
openaire +2 more sources
Mouse Hematopoietic Stem Cell Transplantation
2013Hematopoietic stem cells (HSCs) are capable of self-renewal and multi-lineage reconstitution of hematopoiesis in irradiated transplant recipient mice. As such, bone marrow transplantation (BMT) is a major assay commonly used to examine murine HSC activity.
Hui, Cheng, Paulina H, Liang, Tao, Cheng
openaire +2 more sources
PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Hematology/Oncology Clinics of North America, 2001The successful use of allogeneic HSCT for children with malignant and nonmalignant diseases continues to be limited by the development of acute and chronic GVHD, infectious complications, delayed recovery of the immune system, acute and long-term toxicity, and relapse of disease.
T G, Gross, R M, Egeler, F O, Smith
openaire +2 more sources
Hematopoietic Stem Cell Transplantation in Thalassemia
Hematology/Oncology Clinics of North America, 2023Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only consolidated, potentially curative treatment for patients with transfusion-dependent thalassemia major. In the past few decades, several new approaches have reduced the toxicity of conditioning regimens and decreased the incidence of graft-versus-host disease, improving patients'
Mattia, Algeri +2 more
openaire +2 more sources